RN Mobile Menu

Search form


Rheumatology Network

Pneumococcal Vaccine Not for Senior RA Patients?

While PPSV23 is recommended for senior adults, researchers say there is "uncertainty" about its effectiveness in infection-prone senior adults with rheumatoid arthritis.


Recent Content

In this slideshow, we review the biologics currently approved to treat adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.

(Psoriasis ©ChristineLangerPueschel/Shutterstock.com)

The U.S. Food and Drug Administration has approved brodalumab (Siliq) for the treatment of adults and moderate-to-severe plaque psoriasis.

Baricitinib janus kinase (JAK1 & JAK2) inhibitor drug molecule. (Molekuul_beShut

Patient-reported outcomes are in line with clinical trial results for baricitinib, an international research team reports.

(Combination medications  ©piotr_pabijan/Shutterstock.com)

Rheumatoid arthritis patients who fail previous methotrexate therapy respond better to TNFi–methotrexate combo, compared to a specific triple therapy, researchers say.

(Vaccinese ©adamgregor/Shutterstock.com)

The 23-valent pneumococcal polysaccharide vaccine (PPSV23) does not prevent pneumonia in rheumatoid arthritis patients, a new study finds.

Elderly falls (©Toa55/Shutterstock.com)

Brain changes that occur as a result of small vessel disease negatively effect gait in senior patients, research shows.

(Foot with gout. ©joloei/Shutterstock.com)

For gout patients with suboptimal responses to allopurinol, adding lesinurad may significantly reduce serum urate levels.

By clicking Accept, you agree to become a member of the UBM Medica Community.